Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study

Lignende værker

• Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study
  af: Patrice Chevallier, et al.
  Udgivet: (2015-04-01)
• Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin’s lymphoma by 18F-fluorodeoxyglucose positron emission tomography
  af: Caroline Bodet-Milin, et al.
  Udgivet: (2008-03-01)
• Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma
  af: Thomas E. Witzig, et al.
  Udgivet: (2014-11-01)
• An audit of central venous access devices (CVADs) in pediatric oncology
  af: Deepankar Bhattacharya, et al.
  Udgivet: (2016-01-01)
• Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia
  af: Sébastien Maury, et al.
  Udgivet: (2010-02-01)